AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA BioTech Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict July 14, 2026 — 11:18 pm EDT Written by RTTNews.com for RTTNews -> (RTTNews) - Today's top gainers in the biotech space include NextCure, ahead of its planned merger with a private company that will create a newly branded public entity; Basel Medical, which recently regained Nasdaq compliance; and Outlook Therapeutics, which is awaiting an FDA decision expected by the end of the month, among others. Read on... What is NXTC's next step? NextCure Inc. (NXTC) was the top-performing stock on Tuesday, with shares soaring more than 200% on news of the company entering into a definitive merger agreement with Avere Therapeutics, Inc., a privately held biotechnology company, for an all-stock transaction. The transaction is expected to close in the second half of 2026, and the combined company is expected to operate as Avere Therapeutics, Inc., and trade on Nasdaq under the ticker symbol "AVRX." Avere Therapeutics' lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy. A Phase 2b study of AVR-001 in psoriasis is expected to begin in early 2027, with topline results anticipated in the first half of 2028. Separately, a Phase 2b psoriasis study in China being conducted by Avere's partner, Hansoh, is expected to report results in 2027. NXTC closed Tuesday's trading at $6.58, up 201.83%. BMGL's Nasdaq Woes Eased Shares of Basel Medical Group Ltd (BMGL), a Singapore-based provider of orthopedic and trauma services, sports medicine, and orthopaedic procedures, among others, jumped more than 26% on Tuesday, on no specific news. The company regained compliance with Nasdaq's minimum bid price requirement on July 10, 2026. A 1-for-12 reverse stock split was implemented on June 22, 2026. BMGL closed Tuesday's trading at $8.12, up 26.59%. DYAI On the Move Dyadic International Inc. (DYAI), a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, was up more than 18% on Tuesday. Last week, the company highlighted continued progress across multiple global health collaborations that further validate the capabilities of its proprietary C1 protein production platform for RSV and malaria. DYAI closed Tuesday's trading at $1.21, up 18.63%. NUWE Catches Investors' Eye Nuwellis Inc. (NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, jumped 15% on Tuesday. The company will showcase its Aquadex SmartFlow System at the KidneyBee Summit 2026, taking place July 14-16 at Children's Hospital Colorado in Aurora, Colorado. The Aquadex SmartFlow System enables controlled, predictable fluid removal and is seeing increasing adoption at leading pediatric centers across the United States. NUWE closed Tuesday's trading at $3.22, up 15%. ATAI On Track AtaiBeckley Inc. (ATAI), a clinical-stage biotechnology company developing rapid-acting, durable and convenient mental health treatments, was up 14% on Tuesday. The company's pipeline includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression; VLS-01 (DMT buccal film) for treatment-resistant depression, and EMP-01 for social anxiety disorder. BPL-003 is in Phase 3 clinical development while VLS-01 and EMP-01 are in Phase 2 clinical development. The company expects to report topline data from the Phase 2b trial of VLS-01 in adults living with treatment-resistant depression in Q4, 2026. ATAI closed Tuesday's trading at $5.67, up 14.08%. QNCX Heads into a Busy Second Half Quince Therapeutics Inc. (QNCX) has a couple of clinical trial events lined up for the coming months. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). In a Phase 2a study evaluating LAM-001 in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), clinically meaningful improvement in multiple assessments of lung function was observed. A Phase 2b study in PH-ILD is anticipated to begin in mid-2026. A Phase 2 clinical study of LAM-001 in bronchiolitis obliterans syndrome is ongoing, with data expected in 1Q 2027. The company is planning to initiate a Phase 2 trial of LAM-001 in sarcoidosis associated pulmonary hypertens